Skip to main content
ALGORAE PHARMACEUTICALS LIMITED logo

ALGORAE PHARMACEUTICALS LIMITED — Investor Relations & Filings

Ticker · 1AI ISIN · AU0000296022 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,159 across all filing types
Latest filing 2015-08-17 Regulatory Filings
Country AU Australia
Listing ASX 1AI

About ALGORAE PHARMACEUTICALS LIMITED

https://algoraepharma.com/

Algorae Pharmaceuticals Limited is a biopharmaceutical company focused on the discovery and development of novel therapeutic solutions for complex medical conditions. The company leverages its proprietary artificial intelligence platform, AlgoraeOS, to streamline the drug discovery process and identify synergistic drug combinations. Its research pipeline primarily targets neurodegenerative diseases and other areas of high unmet clinical need. Key development programs include AI-116, a combination therapy aimed at treating dementia and Alzheimer's disease. By integrating advanced computational modeling with traditional pharmacological research, the company seeks to accelerate the transition of candidates from preclinical stages to clinical trials, optimizing therapeutic efficacy and safety profiles.

Recent filings

Filing Released Lang Actions
LCT planning to resume control of NTCELL manufacture 2 pages 51.3KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement from Living Cell Technologies Limited dated 18 August 2015. It announces that the company is finalizing contracts to resume control of the manufacture of NTCELL, a product related to their biotechnology operations. The text includes background information about the company and its products, contact details for further information, and a forward-looking statements disclaimer. There are no financial statements, detailed financial data, or regulatory filings such as annual or quarterly reports. The document is a corporate announcement about operational control changes related to manufacturing, not a financial report or regulatory filing. It is not a report publication announcement since it does not mention any report being attached or published. The content fits best as a general regulatory announcement about company operations, which falls under Regulatory Filings (RNS).
2015-08-17 English
Living Insights Newsletter 2 pages 1.2MB
Investor Presentation Classification · 85% confidence The document is titled 'Living Insights' and is described as a message from the CEO published occasionally. It provides updates on clinical study results, strategic direction, and future plans related to the company's biotechnology products. The content is narrative and informative, focusing on clinical trial progress, strategic updates, and upcoming investor roadshows. There are no detailed financial statements, regulatory filings, or formal report structures such as annual or quarterly reports. The document is longer than 5,000 characters but does not contain substantive financial data or formal financial reporting. It is not a transcript, audit report, or legal proceeding update. It is also not a formal investor presentation or earnings release. The document serves as a corporate update communication to shareholders and interested parties, akin to a newsletter or informational bulletin. Given these characteristics, the document best fits the category of an Investor Presentation (IP) as it provides detailed updates on company strategy, clinical progress, and future plans aimed at investors and stakeholders.
2015-08-04 English
Response to ASX aware letter 5 pages 396.2KB
Regulatory Filings Classification · 95% confidence The document is a letter from ASX Limited to Living Cell Technologies Limited regarding an ASX aware query about the company's announcement on clinical study results. It discusses compliance with ASX Listing Rules 3.1 and 3.1A concerning continuous disclosure obligations. The document is a regulatory inquiry and response about the timing and nature of a prior announcement, not the announcement itself or a financial report. It does not contain financial statements or detailed financial data but is a compliance and regulatory communication. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements and compliance documents.
2015-07-28 English
Appendix 4C - quarterly 7 pages 507.4KB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Appendix 4C Quarterly Cash Flow Report 30 June 2015' and is an ASX announcement. It contains detailed quarterly cash flow statements, including operating, investing, and financing activities, as well as reconciliation of cash and payments to directors. The document is about 13,190 characters long, which is substantial and contains actual financial data for the quarter ended 30 June 2015. The Appendix 4C is a standard quarterly cash flow report required by the ASX for entities admitted on the basis of commitments. This fits the definition of an Interim / Quarterly Report (IR) because it provides comprehensive financial data for a period shorter than a full fiscal year, including substantive financial statements and analysis. It is not merely an announcement or a certification, but the actual report itself. Therefore, the correct classification is IR. Q4 2015
2015-07-26 English
Proposed grant of options to Directors 2 pages 275.3KB
Board/Management Information Classification · 95% confidence The document is an ASX announcement dated 14 July 2015 regarding the proposed grant of options to Directors, which will be subject to shareholder approval at the upcoming AGM. It discusses remuneration alignment and option terms but does not contain financial statements or detailed financial performance data. The document is relatively short (5252 characters) and serves as an announcement of a proposal related to director remuneration rather than a full report or detailed management discussion. It is not a full Annual Report, Interim Report, or Management Report. It is also not a Proxy Solicitation or Voting Results announcement. The content fits best under Board/Management Information (MANG) as it relates to director remuneration proposals and changes in director compensation structure, which is a management/board-related announcement. Confidence is high given the clear focus on director option grants and shareholder approval at AGM.
2015-07-13 English
Update to DIABECELL development strategy 2 pages 51.9KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement from Living Cell Technologies Limited dated 26 June 2015. It provides an update on the development strategy of DIABECELL, a product under development by a joint venture. The content focuses on strategic changes, research and development focus, and operational updates such as staff reductions and clinical trial plans. There are no financial statements, detailed financial performance data, or comprehensive management analysis. The document is a corporate announcement about development strategy and operational changes rather than a financial report or regulatory filing. It does not fit categories like Annual Report, Interim Report, Earnings Release, or Management Reports. It is not a regulatory filing or certification. The document is best classified as a general regulatory announcement about company operations and strategy, which fits the Regulatory Filings (RNS) category as a fallback for miscellaneous announcements that do not fit other specific categories.
2015-06-25 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.